Actively Recruiting
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
Led by HK inno.N Corporation · Updated on 2024-04-29
36
Participants Needed
1
Research Sites
218 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
CONDITIONS
Official Title
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 19 at the time of obtaining the informed consent form
- Planning to receive FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
- ECOG performance status 0 or 1
- Scheduled for RO or R1 surgical resection
- Organ function sufficient for chemotherapy
You will not qualify if you...
- Contraindications to FOLFIRINOX according to drug approval requirements
- Receiving palliative therapy
- History of toxic or hypersensitivity reactions to FOLFIRINOX
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul ST. Mary's Hospital
Seoul, South Korea
Actively Recruiting
Research Team
S
Soyeon Ahn
CONTACT
Y
Yongan Jeong
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here